Case Study: QOL Medical enhances CSID education for healthcare providers with Rizco’s Sucraid® eDetail

QOL Medical boosts CSID education with Rizco as 81% of patients became asymptomatic with Sucraid®

Rizco collaborated with QOL Medical to address the challenge of educating busy healthcare providers about the rare condition Congenital Sucrase-Isomaltase Deficiency (CSID) and its only FDA-approved treatment, Sucraid®. The complexity of the disease state and the need for clear, engaging communication in a fast-paced medical environment presented a significant hurdle.

To solve this, Rizco designed and developed an informative Sucraid® eDetail microsite. The solution featured custom animations, illustrations, and a clean design to simplify complex information about symptoms, diagnosis, and treatment. The project was a significant success, drawing daily interest and engagement from healthcare providers. Anthony D’Elia, Vice President of Marketing at QOL Medical, praised Rizco for delivering a project that was on time, within budget, and exceeded expectations.

QOL Medical